With the new program, patients using Amazon Pharmacy will no longer have to search for and manually enter coupons from the three largest in...

"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...

Indian pharmaceutical companies are becoming more aggressive and increasing their market share and capex. Companies such as Divis, Dr Reddy...

Lupin said it will market Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import.

According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for m...

In 2009, Mylan and Biocon had come together to develop five blockbuster biologic drugs in cancer and pain areas.

Biocon is now exploring new partnerships with pharma companies for its biosimilars, or low-cost copies of biotechnology products.

Biocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...

Biocon dropped more than 7% early to touch their 52-week low of Rs 238 after Pfizer terminated an agreement to sell insulin products.

The NPPA will have to increase MRP of US firm Eli Lilly’s insulin brand, paving the way for price increases of other imported medicines who...

As per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these...

The Bangalore-based firm’s scrip opened at Rs 445, reached an intra-day high of Rs 464.6 before closing at Rs 455, up 12.97% over Monday’s ...

The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...

Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...